From the Journals

Dual Therapy for Coronary Disease: How Safe Is It? 

Adding aspirin to long-term oral anticoagulation in patients with chronic coronary syndrome increased mortality and major bleeding without improving cardiovascular outcomes.

Share

A recent study from the AQUATIC trial revealed that adding aspirin to oral anticoagulation therapy in patients with chronic coronary syndrome increased the risk of cardiovascular and all-cause mortality. Conducted across 51 sites in France with 872 participants who had undergone coronary stent implantation, the double-blind trial was halted early after 2.2 years due to excess deaths among those taking aspirin. Key findings included higher rates of major bleeding and serious adverse events in the aspirin group, highlighting a need to reconsider its use in such high-risk patients.

Original Source(s)

Dual Therapy for Coronary Disease: How Safe Is It? 

Adding aspirin to long-term oral anticoagulation in patients with chronic coronary syndrome increased mortality and major bleeding without improving cardiovascular outcomes.

  • by Kathryn Wighton

  • November 12, 2025

  • 2 min

Related Content

Gut Microbes Signal CAD Risk

Metagenome analysis reveals strain-level functional differences and metabolic pathways that distinguish patients with coronary artery disease from healthy controls.

This Week’s Biopharma News: Clinical Hold for Heart Disease Gene Therapy

Our latest news roundup reports on Novartis’ new radioligand facility in California, new tech for boosting AAV yields, and MeiraGTx’s deal with Eli Lilly

  • November 12, 2025

  • 5 min
Why Do Women Need Less Exercise for the Same Heart Benefit?

Accelerometer data from over 85,000 UK Biobank participants reveal significant sex differences in physical activity benefits for heart disease prevention and survival.